Systemic administration of the selective and potent TRPV4 antagonist, HC-067047, decreased voiding frequency and increased bladder capacity in mice and rats following CYP-induced cystitis (Everaerts et al., 2010c) or repeated variate stress (Merrill and Vizzard, 2014). Here, TRPV4 is linked to chronic cystitis.